March 6, 2012 — New York health insurers will lose state Medicaid contracts if they deny coverage of brand-name contraceptives, unless lower-cost, generic versions "fail first," the state warned on Monday, AP/U-T San Diego reports.
The warning came after the Associated Press reported that some female beneficiaries were told they would have to switch to lower-cost contraceptives unless those versions first failed to prevent pregnancy or resulted in bleeding or nausea (Gormley , AP/U-T San Diego, 3/5). The problem appeared to stem from a rule issued as part of a state Medicaid cost-cutting effort, according to the AP/U-T San Diego.
Under a rule that took effect Oct. 1, private health plans in New York's Medicaid managed care program are required to use generic drugs whenever possible. The state sought to substitute a generic birth control pill for more costly types of contraceptives, such as the monthly NuvaRing or weekly patch, according to the AP/U-T San Diego. Some health plans had denied coverage of the more costly contraceptives, citing the rule (Gormley , AP/U-T San Diego, 3/5).
"If a health plan is not attentive to the needs of its patients, they will no longer be a contracted health plan with New York's Medicaid program," James Introne, state deputy secretary for health, said, adding, "If there is resulting patient discomfort with a health care plan or its policies, it is a situation that the state will remedy." He said that there have not been "a significant level of complaints," but added that ensuring a "woman's ability to access birth control is a priority" for the state (Gormley , AP/U-T San Diego, 3/5).
Repro Health Watch — an exciting new edition of the Women’s Health Policy Report — compiles and distributes media coverage of proposed and enacted state laws and ballot initiatives affecting women's access to comprehensive reproductive health care, as well as litigation in response to those provisions.